{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:59:54Z","timestamp":1790629194569,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472895"],"award-info":[{"award-number":["82472895"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024A04J6605"],"award-info":[{"award-number":["2024A04J6605"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["SL2023A04J02310"],"award-info":[{"award-number":["SL2023A04J02310"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Innovation 2030 Major Program"},{"name":"Special Funds for the Cultivation of Guangdong College Students\u2019 Scientific and Technological Innovation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41417-025-00964-y","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T13:28:05Z","timestamp":1758374885000},"page":"1319-1329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bacillus Calmette-Guerin induces CD8+ T cell infiltration and suppresses tumor progression in microsatellite stable colorectal cancer by downregulating ARID1A"],"prefix":"10.1038","volume":"32","author":[{"given":"Zhiyue","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2284-2265","authenticated-orcid":false,"given":"Nan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-0884","authenticated-orcid":false,"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"964_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"964_CR2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467\u201380.","journal-title":"Lancet"},{"key":"964_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. Jama. 2021;325:669\u201385.","journal-title":"Jama"},{"key":"964_CR4","doi-asserted-by":"publisher","first-page":"795972","DOI":"10.3389\/fimmu.2022.795972","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, et al. Neoadjuvant immunotherapy for MSI-H\/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol. 2022;13:795972.","journal-title":"Front Immunol"},{"key":"964_CR5","doi-asserted-by":"publisher","first-page":"1120684","DOI":"10.3389\/fimmu.2023.1120684","volume":"14","author":"J Zhu","year":"2023","unstructured":"Zhu J, Lian J, Xu B, Pang X, Ji S, Zhao Y, et al. Neoadjuvant immunotherapy for colorectal cancer: right regimens, right patients, right directions? Front Immunol. 2023;14:1120684.","journal-title":"Front Immunol"},{"key":"964_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fimmu.2020.00369","volume":"11","author":"E Picard","year":"2020","unstructured":"Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 2020;11:369.","journal-title":"Front Immunol"},{"key":"964_CR7","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3389\/fimmu.2020.02039","volume":"11","author":"A Lin","year":"2020","unstructured":"Lin A, Zhang J, Luo P. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front Immunol. 2020;11:2039.","journal-title":"Front Immunol"},{"key":"964_CR8","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1038\/s41388-023-02835-y","volume":"42","author":"PM Kasi","year":"2023","unstructured":"Kasi PM, Hidalgo M, Jafari MD, Yeo H, Lowenfeld L, Khan U, et al. Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer. Oncogene. 2023;42:3252\u20139.","journal-title":"Oncogene"},{"key":"964_CR9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","volume":"41","author":"J Li","year":"2023","unstructured":"Li J, Wu C, Hu H, Qin G, Wu X, Bai F, et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell. 2023;41:1152\u20131169.e7.","journal-title":"Cancer Cell"},{"key":"964_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566\u201376.","journal-title":"Nat Med"},{"key":"964_CR11","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1080\/21645515.2021.2007711","volume":"17","author":"M Qu","year":"2021","unstructured":"Qu M, Zhou X, Li H. BCG vaccination strategies against tuberculosis: updates and perspectives. Hum Vaccines Immunother. 2021;17:5284\u201395.","journal-title":"Hum Vaccines Immunother"},{"key":"964_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394.","journal-title":"Eur Urol"},{"key":"964_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41768-8","volume":"14","author":"E Moreo","year":"2023","unstructured":"Moreo E, Jarit-Cabanillas A, Robles-Vera I, Uranga S, Guerrero C, G\u00f3mez AB, et al. Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung. Nat Commun. 2023;14:6090.","journal-title":"Nat Commun"},{"key":"964_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16067-0","volume":"7","author":"ME Morra","year":"2017","unstructured":"Morra ME, Kien ND, Elmaraezy A, Abdelaziz OAM, Elsayed AL, Halhouli O, et al. Early vaccination protects against childhood leukemia: a systematic review and meta-analysis. Sci Rep. 2017;7:15986.","journal-title":"Sci Rep."},{"key":"964_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/joim.13037","volume":"288","author":"M Kremenovic","year":"2020","unstructured":"Kremenovic M, Schenk M, Lee DJ. Clinical and molecular insights into BCG immunotherapy for melanoma. J Intern Med. 2020;288:625\u201340.","journal-title":"J Intern Med"},{"key":"964_CR16","doi-asserted-by":"publisher","first-page":"110.e19","DOI":"10.1016\/j.urolonc.2014.09.016","volume":"33","author":"PJ Olbert","year":"2015","unstructured":"Olbert PJ, Kesch C, Henrici M, Subtil FS, Honacker A, Hegele A, et al. TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells. Urol Oncol. 2015;33:110.e19\u201327.","journal-title":"Urol Oncol"},{"key":"964_CR17","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1021\/acs.molpharmaceut.8b00691","volume":"15","author":"MA Shetab Boushehri","year":"2018","unstructured":"Shetab Boushehri MA, Lamprecht A. TLR4-based immunotherapeutics in cancer: a review of the achievements and shortcomings. Mol Pharm. 2018;15:4777\u2013800.","journal-title":"Mol Pharm"},{"key":"964_CR18","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.molmed.2023.04.005","volume":"29","author":"F Jin","year":"2023","unstructured":"Jin F, Yang Z, Shao J, Tao J, Rei\u00dffelder C, Loges S, et al. ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications. Trends Mol Med. 2023;29:646\u201358.","journal-title":"Trends Mol Med"},{"key":"964_CR19","doi-asserted-by":"publisher","first-page":"102287","DOI":"10.1016\/j.ctrv.2021.102287","volume":"100","author":"J Mullen","year":"2021","unstructured":"Mullen J, Kato S, Sicklick JK, Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev. 2021;100:102287.","journal-title":"Cancer Treat Rev"},{"key":"964_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.7150\/jca.41296","volume":"11","author":"T Jiang","year":"2020","unstructured":"Jiang T, Chen X, Su C, Ren S, Zhou C. Pan-cancer analysis of ARID1A alterations as biomarkers for immunotherapy outcomes. J Cancer. 2020;11:776\u201380.","journal-title":"J Cancer"},{"key":"964_CR21","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","volume":"187","author":"MB Maxwell","year":"2024","unstructured":"Maxwell MB, Hom-Tedla MS, Yi J, Li S, Rivera SA, Yu J, et al. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell. 2024;187:3390\u20133408.e19.","journal-title":"Cell"},{"key":"964_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.humpath.2016.02.004","volume":"53","author":"LH Lee","year":"2016","unstructured":"Lee LH, Sadot E, Ivelja S, Vakiani E, Hechtman JF, Sevinsky CJ, et al. ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. Hum Pathol. 2016;53:97\u2013104.","journal-title":"Hum Pathol"},{"key":"964_CR23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.humpath.2014.04.009","volume":"45","author":"A Chou","year":"2014","unstructured":"Chou A, Toon CW, Clarkson A, Sioson L, Houang M, Watson N, et al. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol. 2014;45:1697\u2013703.","journal-title":"Hum Pathol"},{"key":"964_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000369140","volume":"88","author":"SY Lee","year":"2015","unstructured":"Lee SY, Kim DW, Lee HS, Ihn MH, Oh HK, Park DJ, et al. Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies. Oncology. 2015;88:234\u201340.","journal-title":"Oncology"},{"key":"964_CR25","doi-asserted-by":"publisher","first-page":"18404","DOI":"10.3748\/wjg.v20.i48.18404","volume":"20","author":"XL Wei","year":"2014","unstructured":"Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL, Zeng ZL, et al. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol. 2014;20:18404\u201312.","journal-title":"World J Gastroenterol"},{"key":"964_CR26","first-page":"3920","volume":"10","author":"HX Xu","year":"2020","unstructured":"Xu HX, Zhu P, Zheng YY, Zhang X, Chen YQ, Qiao LC, et al. Molecular screening and clinicopathologic characteristics of Lynch-like syndrome in a Chinese colorectal cancer cohort. Am J Cancer Res. 2020;10:3920\u201334.","journal-title":"Am J Cancer Res"},{"key":"964_CR27","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1038\/s41379-020-0612-2","volume":"33","author":"J Wang","year":"2020","unstructured":"Wang J, Li R, He Y, Yi Y, Wu H, Liang Z. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas. Mod Pathol. 2020;33:2591\u2013601.","journal-title":"Mod Pathol"},{"key":"964_CR28","doi-asserted-by":"publisher","first-page":"101685","DOI":"10.1016\/j.tranon.2023.101685","volume":"33","author":"D Sun","year":"2023","unstructured":"Sun D, Zhao H, Zhou H, Tao J, Li T, Zhu J, et al. ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma. Transl Oncol. 2023;33:101685.","journal-title":"Transl Oncol"},{"key":"964_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/path.5849","volume":"256","author":"K Heinze","year":"2022","unstructured":"Heinze K, Nazeran TM, Lee S, Kr\u00e4mer P, Cairns ES, Chiu DS, et al. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8(+) TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol. 2022;256:388\u2013401.","journal-title":"J Pathol"},{"key":"964_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","volume":"24","author":"J Shen","year":"2018","unstructured":"Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24:556\u201362.","journal-title":"Nat Med"},{"key":"964_CR31","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.clgc.2021.12.001","volume":"20","author":"A Awadalla","year":"2022","unstructured":"Awadalla A, Zahran MH, Abol-Enein H, Zekri AN, Elbaset MA, Ahmed AE, et al. Identification of different miRNAs and their relevant miRNA targeted genes involved in sister chromatid cohesion and segregation (SCCS)\/chromatin remodeling pathway on T1G3 urothelial carcinoma (UC) response to BCG immunotherapy. Clin Genitourin Cancer. 2022;20:e181\u2013e189.","journal-title":"Clin Genitourin Cancer"},{"key":"964_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.euo.2021.11.002","volume":"5","author":"JVW Bacon","year":"2022","unstructured":"Bacon JVW, M\u00fcller DC, Ritch E, Annala M, Dugas SG, Herberts C, et al. Somatic features of response and relapse in non-muscle-invasive bladder cancer treated with Bacillus Calmette\u2013Gu\u00e9rin immunotherapy. Eur Urol Oncol. 2022;5:677\u201386.","journal-title":"Eur Urol Oncol"},{"key":"964_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00725-4","volume":"8","author":"QD Xia","year":"2024","unstructured":"Xia QD, Sun JX, Yao ZP, Lu JL, Liu CQ, Xu JZ, et al. The role of TERT C228T and KDM6A alterations and TME in NMIBC treated with BCG. NPJ Precis Oncol. 2024;8:216.","journal-title":"NPJ Precis Oncol"},{"key":"964_CR34","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jamaoncol.2023.3323","volume":"9","author":"OE Emiloju","year":"2023","unstructured":"Emiloju OE, Sinicrope FA. Neoadjuvant immune checkpoint inhibitor therapy for localized deficient mismatch repair colorectal cancer: a review. JAMA Oncol. 2023;9:1708\u201315.","journal-title":"JAMA Oncol"},{"key":"964_CR35","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.21.02691","volume":"40","author":"Z Jin","year":"2022","unstructured":"Jin Z, Sinicrope FA. Mismatch repair-deficient colorectal cancer: building on checkpoint blockade. J Clin Oncol. 2022;40:2735\u201350.","journal-title":"J Clin Oncol"},{"key":"964_CR36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/cells12020258","volume":"12","author":"I Yu","year":"2023","unstructured":"Yu I, Dakwar A, Takabe K. Immunotherapy: recent advances and its future as a neoadjuvant, adjuvant, and primary treatment in colorectal cancer. Cells. 2023;12:258","journal-title":"Cells"},{"key":"964_CR37","doi-asserted-by":"publisher","first-page":"749.","DOI":"10.3390\/medicina57080749","volume":"57","author":"J Dobruch","year":"2021","unstructured":"Dobruch J, Oszczudlowski M. Bladder cancer: current challenges and future directions. Medicina (Kaunas). 2021;57:749.","journal-title":"Medicina (Kaunas)"},{"key":"964_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/imm.13586","volume":"168","author":"YM Kim","year":"2023","unstructured":"Kim YM, Choi JO, Cho YJ, Hong BK, Shon HJ, Kim BJ, et al. Mycobacterium potentiates protection from colorectal cancer by gut microbial alterations. Immunology. 2023;168:493\u2013510.","journal-title":"Immunology"},{"key":"964_CR39","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.1002\/jcp.26273","volume":"233","author":"R Moradi-Marjaneh","year":"2018","unstructured":"Moradi-Marjaneh R, Hassanian SM, Fiuji H, Soleimanpour S, Ferns GA, Avan A, et al. Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer. J Cell Physiol. 2018;233:5613\u201322.","journal-title":"J Cell Physiol"},{"key":"964_CR40","doi-asserted-by":"publisher","first-page":"1136248","DOI":"10.3389\/fonc.2023.1136248","volume":"13","author":"B Fontana","year":"2023","unstructured":"Fontana B, Gallerani G, Salamon I, Pace I, Roncarati R, Ferracin M. ARID1A in cancer: friend or foe? Front Oncol. 2023;13:1136248.","journal-title":"Front Oncol"},{"key":"964_CR41","doi-asserted-by":"publisher","first-page":"1848.","DOI":"10.3390\/ijms25031848","volume":"25","author":"DT Morgos","year":"2024","unstructured":"Morgos DT, Stefani C, Miricescu D, Greabu M, Stanciu S, Nica S. Targeting PI3K\/AKT\/mTOR and MAPK signaling pathways in gastric cancer. Int J Mol Sci. 2024;25:1848.","journal-title":"Int J Mol Sci"},{"key":"964_CR42","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378\u201384.","DOI":"10.1038\/nature21386"},{"key":"964_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00018-022-04331-0","volume":"79","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Li Y, Ran X, Wang D, Zheng X, Zhang M, et al. Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-\u03baB\/IL-6 signaling pathway. Cell Mol Life Sci. 2022;79:311.","journal-title":"Cell Mol Life Sci"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00964-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00964-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00964-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T23:02:35Z","timestamp":1765753355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00964-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00964-y","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}